Drug specific antibodies: T-cell epitope-lipopeptide conjugates are potent adjuvants for small antigens in vivo and in vitro
- PMID: 9439766
- DOI: 10.1016/s0192-0561(97)00069-6
Drug specific antibodies: T-cell epitope-lipopeptide conjugates are potent adjuvants for small antigens in vivo and in vitro
Abstract
To generate conventional or monoclonal antibodies for the serological detection of drugs, antibiotics, toxins and other low molecular mass substances, a suitable and effective adjuvant is needed. Lipopeptides derived from a major component of the bacterial cell wall constitute potent nontoxic and nonpyrogenic immunoadjuvants when mixed with conventional antigens. Here we demonstrate that the synthetic lipopeptide N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2R,S)-propyl]-(R)-cysteinyl- serine (P3CS) coupled to a Th-cell epitope (P3CS-Th) can efficiently enhance the specific immune response against low molecular weight compounds in different species. In the presence of the synthetic lipopeptide P3CS-Th, the peptides which are per se non-immunogenic stimulated a specific humoral immune response in mice after intraperitoneal application. Mixtures containing adjuvants without the Th sequence showed no significant antibody induction. A marked enhancement of the humoral immune response was obtained with the low molecular mass antigens Iturin AL, Herbicolin A and Microcystin (MLR) coupled to poly-l-lysin (MLR-PLL), in rabbits and in chickens. Lipopeptide-Th cell epitope conjugates also constituted adjuvants for the in vitro immunization of either human mononuclear cells or mouse B-cells with MLR-PLL; after fusion of the immunized cultures with the heteromyeloma cell lines CB-F7 or the mouse myeloma cell line SP 2/0, respectively, we observed a significantly increased yield of antibody secreting hybridomas.
Similar articles
-
Preparation of human and murine monoclonal antibodies: antigens combined with or conjugated to lipopeptides constitute potent immunogens for in vitro and in vivo immunizations.Hum Antibodies Hybridomas. 1990;1(3):137-44. Hum Antibodies Hybridomas. 1990. PMID: 2103357
-
Generation of antibodies directed against the low-immunogenic peptide-toxins microcystin-LR/RR and nodularin.Int J Immunopharmacol. 2000 May;22(5):339-53. doi: 10.1016/s0192-0561(99)00086-7. Int J Immunopharmacol. 2000. PMID: 10708882
-
Conjugates of synthetic lymphocyte-activating lipopeptides with segments from HIV proteins induce protein-specific antibody formation.Biol Chem Hoppe Seyler. 1990 Oct;371(10):967-75. doi: 10.1515/bchm3.1990.371.2.967. Biol Chem Hoppe Seyler. 1990. PMID: 1706188
-
Synthetic lipopeptides as novel adjuvants.Res Immunol. 1992 Jun;143(5):548-53; discussion 579-80. doi: 10.1016/0923-2494(92)80067-u. Res Immunol. 1992. PMID: 1439136 Review.
-
Bacterial lipopeptides constitute efficient novel immunogens and adjuvants in parenteral and oral immunization.Behring Inst Mitt. 1997 Feb;(98):390-9. Behring Inst Mitt. 1997. PMID: 9382763 Review.
Cited by
-
Immunostimulation by the synthetic lipopeptide P3CSK4: TLR4-independent activation of the ERK1/2 signal transduction pathway in macrophages.Immunology. 2001 May;103(1):49-60. doi: 10.1046/j.1365-2567.2001.01203.x. Immunology. 2001. PMID: 11380692 Free PMC article.
-
Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles.World J Microbiol Biotechnol. 2015 Aug;31(8):1177-93. doi: 10.1007/s11274-015-1880-8. Epub 2015 Jun 4. World J Microbiol Biotechnol. 2015. PMID: 26041368 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous